Literature DB >> 7520026

Expression of the co-stimulatory molecule B7 on melanoma cells.

P Hersey1, Z Si, M J Smith, W D Thomas.   

Abstract

The induction of T-cell responses against tumor cells is believed to depend on both recognition of antigen and receipt of co-stimulatory signals from interaction of ligands such as B7 with its receptors CD28 or CTLA-4 on T cells. In the present study the expression of B7 on cultured human melanoma cells was studied at the mRNA level by reverse PCR analysis and surface expression by flow cytometric analysis with monoclonal antibodies (MAbs). PCR analysis revealed mRNA for B7 in 3 of 6 (50%) cultured primary melanoma and 8 of 19 (42%) cultures of metastatic melanoma. Analysis of B7 expression by flow cytometry using the BB1 MAb revealed low levels of expression in 3 of 10 melanoma that had mRNA for B7. In 2 of the latter (but not 4 other PCR+ lines) expression could be increased by culture in GM-CSF, IL-2, IFN-gamma and IFN-alpha 2. Our results indicate that although mRNA for B7 is present in 40-50% of melanoma cell lines, expression at the protein level is at low or undetectable levels in the majority of the cell lines. Expression of B7 protein was also not detected in studies on tissue sections from 11 primary and 9 metastatic melanomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520026     DOI: 10.1002/ijc.2910580413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.

Authors:  B Melichar; M A Nash; R Lenzi; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Authors:  Guillaume Sarrabayrouse; Christine Pich; Raphaël Moriez; Virginie Armand-Labit; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

3.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

Authors:  David M Woods; Karrune Woan; Fengdong Cheng; Hongwei Wang; Patricio Perez-Villarroel; Calvin Lee; Maritza Lienlaf; Peter Atadja; Edward Seto; Jeffrey Weber; Eduardo M Sotomayor; Alejandro Villagra
Journal:  Melanoma Res       Date:  2013-10       Impact factor: 3.599

4.  T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.

Authors:  Aude G Chapuis; Ilana M Roberts; John A Thompson; Kim A Margolin; Shailender Bhatia; Sylvia M Lee; Heather L Sloan; Ivy P Lai; Erik A Farrar; Felecia Wagener; Kendall C Shibuya; Jianhong Cao; Jedd D Wolchok; Philip D Greenberg; Cassian Yee
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

5.  Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.

Authors:  A F Kirkin; T R Petersen; A C Olsen; L Li; P thor Straten; J Zeuthen
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

6.  Heterologous expression of human costimulatory molecule B7-2 and construction of B7-2 immobilized polyhydroxyalkanoate nanoparticles for use as an immune activation agent.

Authors:  Ming-Chuan Li; Qian-Qian Liu; Xiao-Yun Lu; Ya-Li Zhang; Lei-Lei Wang
Journal:  BMC Biotechnol       Date:  2012-07-30       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.